Royalty Pharma plc – Material Contracts Watch

from 10-K 2 pages Confidential Position: Senior Adviser, Reporting to the Chief Executive Officer. Dedication of Time: It Is Our Expectation That You Will Work at Least Half Time on Company Matters. Base Salary: Your Annual Base Salary Will Be $700,000. Your Annual Salary Will Be Paid Less Applicable Deductions and Withholdings, and Will Be Payable Pursuant to the Company’s Normal Payroll Practices. Bonus: You Will Not Be Entitled to Any Bonus. Employment at Will: Your Employment With the Company Will Be on an At-Will Basis and Is Not Guaranteed for Any Specific Term. Your Employment May Be Terminated at Any Time by the Company, With or Without Prior Notice and for Any Reason or No Reason

from 10-Q 4 pages Fourth Supplemental Indenture Dated as of June 9, 2025 Supplementing That Certain Indenture Dated as of September 2, 2020 Among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee

from 10-Q 5 pages Deed of Indemnity

from 10-Q 9 pages Form of Executive Officer Offer Letter

from 8-K 68 pages Dated: May 2025 Amendment and Restatement Agreement Between Royalty Pharma plc and Royalty Pharma Holdings Ltd and Rpi US Partners 2019, LP and Rpi International Holdings 2019, LP and Rpi International Partners 2019, LP and Rpi US Feeder 2019, LP and Rpi International Feeder 2019, LP and Rpi Epa Vehicle, LLC and the Internalization Shareholders and Pl Rph Aiv, LLC in Relation to an Exchange Agreement Dated 16 June 2020, as Amended and Restated on 29 December 2023 and 31 December 2024

from 8-K 53 pages Dated: 31 December 2024

from 10-Q 39 pages Second Amended and Restated Management Agreement Dated as of October 3, 2022

from 10-Q 18 pages Amended and Restated Management Agreement Dated as of October 3, 2022

from 10-Q 19 pages Amended and Restated Management Agreement Dated as of October 3, 2022

from 8-K 50 pages Underwriting Agreement $1,300,000,000 Royalty Pharma plc 2.150% Senior Unsecured Notes Due 2031 3.350% Senior Unsecured Notes Due 2051 Underwriting Agreement

from 8-K 11 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Amendment No. 2 to Amended and Restated Purchase and Sale Agreement

from S-1 29 pages Registration Rights Agreement

from S-1 52 pages First Supplemental Indenture Dated as of September 2, 2020 Supplementing That Certain Indenture Dated as of September 2, 2020 Among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee 0.750% Senior Notes Due 2023 1.200% Senior Notes Due 2025 1.750% Senior Notes Due 2027 2.200% Senior Notes Due 2030 3.300% Senior Notes Due 2040 3.550% Senior Notes Due 2050

from S-1 68 pages Indenture Dated as of September 2, 2020 Among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee

from S-1 17 pages Royalty Pharma plc 2020 Independent Director Equity Incentive Plan

from S-1 39 pages Amended and Restated Management Agreement Dated as of 11 June, 2020

from S-1 14 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Amendment No. 7 Research, Development and Commercialization Agreement, Dated May 24, 2004 by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated

from S-1 26 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Amendment No. 5 to Research, Development and Commercialization Agreement, Dated May 24, 2004, by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated Background

from S-1 16 pages Amendment No. 2 to Research, Development and Commercialization Agreement, Dated May 24, 2004, by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated Background

from S-1 9 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Amendment No. 1 to Research, Development and Commecialization Agreement (The “Existing Agreement”) Dated May 24, 2004 by and Between Vertex Pharmaceuticals Incorporated (“Vertex”) and Cystic Fibrosis Foundation Therapeutics Incorporated